CANF
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Ref P/E N/A, P/B 0.68, P/S 15.39
- P/B ratio of 0.68 suggests the stock is undervalued relative to assets
- P/S ratio of 15.39 is excessively high for a company with shrinking revenue
- No Graham Number available due to lack of earnings
Ref Revenue Growth -43.30%
- Single analyst target price of $50.00 suggests extreme upside potential if a clinical breakthrough occurs
- Revenue growth is deeply negative (-43.3%)
- Forward P/E is negative
Ref 5Y Change -99.4%
- 5-year price change of -99.4%
- Consistent history of missing earnings estimates by wide margins
Ref Piotroski 5/9, Debt/Equity 0.01
- Piotroski F-Score of 5/9 is stable
- Debt/Equity is nearly zero
- Quick Ratio of 3.13 is healthy
- ROE is deeply negative (-178.24%)
Ref Dividend Yield N/A
- No dividend history
- Zero payout ratio
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for CANF and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
CANF
Can-Fite BioPharma Ltd.
Primary
|
-99.4% | -91.8% | -87.6% | -68.4% | -9.9% | -4.3% |
|
QUCY
Mainz Biomed N.V.
Peer
|
-98.2% | -91.0% | -84.9% | -67.3% | -19.4% | +9.9% |
|
BRTX
BioRestorative Therapies, Inc.
Peer
|
-99.5% | -93.0% | -85.2% | -84.5% | +8.1% | -7.9% |
|
BIAF
bioAffinity Technologies, Inc.
Peer
|
-99.5% | -98.4% | -92.9% | -86.5% | +9.8% | -1.5% |
|
NXGL
NEXGEL, Inc.
Peer
|
-78.5% | -49.8% | -73.0% | -70.1% | -8.6% | +18.5% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
CANF
Can-Fite BioPharma Ltd.
|
BEARISH | $6.23M | - | -178.2% | -% | $2.91 | |
|
QUCY
Mainz Biomed N.V.
|
BEARISH | $6.09M | - | -488.3% | -% | $0.49 | Compare |
|
BRTX
BioRestorative Therapies, Inc.
|
BEARISH | $6.39M | - | -320.5% | -% | $0.25 | Compare |
|
BIAF
bioAffinity Technologies, Inc.
|
BEARISH | $6.07M | - | -245.2% | -217.5% | $1.35 | Compare |
|
NXGL
NEXGEL, Inc.
|
BEARISH | $6.41M | - | -52.7% | -26.3% | $0.76 | Compare |
SEC Filings
Recent regulatory filings from the SEC EDGAR database
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning CANF from our newsroom.